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Available online 5 August 2009Evidence-based clinical practice guidelines (CPGs) are increas-
ingly seen as important tools to facilitate clinical governance
that improves patient care and health outcomes. They assist
in the determination of how diseases and other health condi-
tions can be most effectively and appropriately prevented,
diagnosed, treated and managed. CPGs are used by the health-
care administrators in judging the provision of health care and
in improving quality. In most developed countries, guidelines
are promoted at all levels of health care.
Evidence-based clinical practice guidelines (EB-CPG) are
systematically developed statements to assist practitioner and
patient decisions about appropriate health care for speciﬁc
clinical circumstances. They are different from consensus state-
ment or opinion which are basically a summary of the positions
of groups of individuals (usually experts) and their own selec-
tion (? bias) regarding a particular health care problem. It is
also different from (but interlinked with) clinical pathway
(CP) which is a patient care management tool that organizes,
sequences, and times of all major interventions of nurses, phy-
sicians, and various departments for a particular health condi-
tion (e.g., Heart Failure, acute chest pain, etc.) or case type
(e.g., patient on IABP (intra-aortic balloon pump) or ECMO
(extra-corporeal membrane oxygenation) or patient subset
(e.g., diabetic IHD).1016-7315 ª 2009 King Saud University. All rights reserved. Peer-
review under responsibility of King Saud University.
doi:10.1016/j.jsha.2009.06.004
Production and hosting by ElsevierEB-CPGs are also different from evidence-linked clinical
recommendations (CR). The clinical recommendations are
interpretation of the evidence and translating it into an action
statement or series of action statements. There should be a
clear and direct relationship between a CR and the evidence
which this CR was based upon. From this brief description,
the reader will realize that CPGs are more comprehensive in
nature and rigorous in development process.
Good CPGs should be:
1. Valid – leading to the results expected of them.
2. Reproducible – if using the same evidence, other guideline
groups would come to the same results.
3. Cost-effective – reducing the inappropriate use of
resources.
4. Representative/multidisciplinary – by involving key groups
and their interests.
5. Clinically applicable – patient populations affected should
be unambiguously deﬁned.
6. Flexible – by identifying the expectations relating to recom-
mendations as well as patient preferences.
7. Clear – unambiguous language, which is readily understood
by clinicians and patients.
8. Reviewable – the date and process of review should be
stated.
9. Amenable to clinical audit – the guidelines should be capa-
ble of translation into explicit audit criteria.
The development of CPGs with evidence based methodol-
ogy not only requires extensive effort, resources, manpower
and expertise but also is time consuming. Fig. 1 summarizes
the ideal process of CPGs development. Due to the extensive
effort and resources that are needed, development of CPGs
Figure 1 CPGs development process.
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entiﬁc bodies that have enough resources to accomplish this
difﬁcult task. It can take between 2 and 4 years from a team
of experts with highly skilled methodologists to complete a
single EB-CPG.
In our region one frequently sees the professional societies/
associations taking one of three positions
1. Not addressing the issue at all (ignore).
2. Develop their own guidelines.
3. Adopt internationally published guidelines from correspon-
dents respected scientiﬁc societies/associations in the devel-
oped countries (like the AHA or ACC or STS).
The regional societies that are taking the ﬁrst position may
be considered as failing to respond to the professional needs of
their members. Very few are brave enough to try to develop
CPGs. Due to the lack of expertise and resources, theirproduct has low quality if appraised by a clinically validated
tool like AGREE instrument. Applying the AGREE instru-
ment for guidelines appraisal on some of our regionally pro-
duced guidelines may reveal several defects in one or more of
the 6 domains of this instrument. Table 1 summarizes these
6 domains and the items of each domain.
In the developed world there are scientiﬁc methodological
bodies that accredit, regulate and monitor the process and
quality of the method of generation of CPG. In our region
there is no such kind of methodological bodies except the pio-
neering work of the National and Gulf center for EBM
(NGCEBM) in the ﬁeld of Guideline adaptation and endorse-
ment . Unfortunately this center does not have the regulatory
or monitoring power. The NGCEBM hopes that this power
may come through the collaboration with the professional
societies like the SHA. Also, the center is linked to the
G.I.N (guideline International Network) and to GRADE
(Grades of Recommendation Assessment, Development and
Table 1 AGREE instrument ‘‘Appraisal of Guidelines REsearch and Evaluation’’.
Domain No. of items Item description
1. Scope and purpose 3 1. The overall objective(s) of the guideline should be speciﬁcally described
2. The clinical question(s) covered by the guideline should be speciﬁcally described
3. The patients to whom the guideline is meant to apply should be speciﬁcally described
2. Stakeholder involvement 4 4. Provide information about: composition and relevant expertise of the guideline
development group
5. Involve patients in their development
6. Clearly deﬁne the target users
7. Piloting prior to publication
3. Rigour of development 7 8. Proper information about search strategy
9. Proper information about Inclusion and exclusion criteria for selecting the evidence
10. Proper information about Methods used to formulate the recommendations
11. Recommendations are explicitly linked to supporting evidence
12. Proper discussion of the health beneﬁts, side eﬀects, and risks
13. The guideline should be externally reviewed by experts prior to publication
14. A procedure for updating the guideline should be provided
4. Clarity and presentation 4 15. The recommendations should be speciﬁc and unambiguous
16. The diﬀerent options for diagnosis and/or treatment of the condition should be clearly
presented
17. Key recommendations should be easily identiﬁable
18. The guideline should be supported with tools for application
5. Applicability 3 19. The potential organizational barriers in applying the recommendations should be
discussed
20. The potential cost implications of applying the recommendations should be considered
21. The guideline should presents key review criteria for monitoring and audit purposes
6. Editorial independence 2 22. The guideline should be editorially independent from the funding body
23. Conﬂicts of interest of guideline development members should be recorded
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logical function but still very far from the authentication or
accreditation regulatory function that should be exerted with
the collaboration professional societies. Till now, it is still fre-
quently seen for CPGs to be developed based on the consensus
among experts. Such approach is not only incongruent with
evidence based health care but also has serious limitations that
can lead to ﬂawed conclusions. CPGs should be based on the
systematic identiﬁcation and synthesis of the best available sci-
entiﬁc evidence. Clinical practice guidelines are only effective if
they are perceived to be helpful and are actually used in clinical
decision-making.
Illustrating the shortcomings of the two previous positions
(ignore or develop), it may be understandable why several soci-
eties in our region are taking the 3rd position which is adoption
of the well-developed internationally recognized guidelines.
The leaders of these professional societies do not ﬁnd a ratio-
nale of ‘‘re-inventing the wheel’’. After the adoption of the
internationally published guidelines, the utilization of it can
be either
1. Adopt the guideline (same language/format).
2. Keep the text but change the format.
3. Translate the guideline (in some countries that the practice
is not in English).
4. Use the guideline as literature(review of evidence).
In our region, most of countries take either the 1st or the
4th position, while others (like Syria or French speaking health
authorities in Lebanon or North Africa), they do translate the
originally English-written CPGs. Very few try to simplify the
CPGs by doing some changes in its format.In fact even Guideline adoption of EB-CPGs can have seri-
ous limitations. The de novo CPGs are developed by a group
who are not necessarily considering the local peculiarities
regarding disease prevalence, resources, priorities and
expertise.
The non-local developers of guidelines may not address the
following points:
 the purpose of the guidelines, including their scope and
target audience, can be different;
 the guidelines should address an issue of national or regio-
nal signiﬁcance, and should have national or regional
application;
 the guidelines should address priority issues such as, for
example, health care areas where there are signiﬁcant vari-
ations in clinical practice, or where the health costs and/or
burdens are high; and
 the guidelines should be developed under the auspices of a
person or group of recognized professional standing, capa-
ble of attracting broad multidisciplinary participation at a
high level.
The adoption of CPG has therefore been criticized and
numerous references have reported the lack of consistency
amongCPGs, the difﬁculty in use, the variable quality andmore
importantly the failure to show a signiﬁcant impact on outcome.Guideline adaptation
Guideline adaptation is the systematic approach to the
endorsement and/or modiﬁcation of a guideline produced in
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different context. Adaptation may be used as an alternative
to developing a new guideline. Adaptation of an existing
guideline minimizes duplication of effort (in both evidence
review and development of recommendations); improves and
‘‘speeds up’’ production; maximizes quality; and promotes
consistency.
The international ADAPTE Collaboration recommends
the use of the ADAPTE guidance on guideline adaptation .
The adaptation of an existing guideline is depicted in Fig. 2
and involves:
 Selecting a topic (high impact; high volume; high cost;
improvement possible).
 Formulation of clinical question.
 Searching for and retrieving existing Evidence Based
Guidelines.
 Assessing: the Quality and Applicability rigorously.
 Accepting (Endorsing) an existing guideline OR producing
a customized guideline from one or more existing published
EB-CPG.
Six core principles underlying the development of guideline
adaptation process:
1. Guideline should be outcome focused.
2. Guidelines should be based on the best available evidence
and should include a statement about the strength of rec-
ommendations Like using the GRADE classiﬁcation).
3. The method used to synthetize the available evidence
should be the strongest applicable.Figure 2 Practice guidelines eva4. The process of guideline development should be multidisci-
plinary and should include consumers(patients and health
care providers).
5. Guidelines should be ﬂexible and capable of adapting to
varying local conditions.
6. The validity and usefulness of the guidelines should be
evaluated; and
The process of CPG adaptation should be followed by three
other extremely important processes which are (see Fig. 3):
1. CPGs endorsement
2. CPGs publication, dissemination and implementation
3. CPGs revision (on a pres-set time interval or whenever a
new evidence is released)
The SHA should identify any barriers to acceptance and
implementation of the guidelines and work with members of
target groups to develop ways for overcoming these barriers.
Guidelines should be presented in a format and style suitable
for the target users.
Strategies for active dissemination and implementation de-
pend on the nature of the guidelines and the target users and
may include:
 the use of brochures or posters;
 using the communication links developed by professional
bodies and other groups;
 asking respected clinical leaders to promote the guidelines;
 using the education processes of appropriate colleges and
other groups;luation and adaptation cycle.
Figure 3 Summary of the ADAPTE process.
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quality improvement, within relevant organizations;
 discussing the guidelines at conferences, seminars and other
professional meetings; and
 using the services of a communications professional.
The passive dissemination of guidelines has limited value in
changing practitioners’ behavior.
Strategies for evaluation should consider:
how well were they disseminated? For example, how many
were accessed online?
is the general trend in clinical practice moving towards the
guideline recommendations?
have the guidelines contributed to any speciﬁc changes in
clinical practice? For example, compare clinical practice
in areas where the guidelines have been heavily promoted
with practice in areas where they have not been promoted;
how have the guidelines affected consumers’ (patient and
doctors) knowledge and understanding?
have health outcomes changed?As for the Revision a date should be set for revision of the
guidelines. The recommendation that this occurs every 2–4
years but it may have to be more often where the subject mat-
ter or circumstances are prone to rapid change. A Watch
group should monitor the possible emergence of a new evi-
dence that can signiﬁcantly impact or change the current
CPGs.
Conclusion
The professional societies like the SHA should support health
professionals in cardiac ﬁelds in the Kingdom of Saudi Arabia
and the Gulf Cooperating Countries (GCC) by the proper
adaptation (not adoption) of Evidence based clinical practice
guidelines. Also SHA may play an pivotal role and be effective
in transferring evidence into practice by executing a full range
of strategies related to the ﬁelds of CPG dissemination, imple-
mentation, evaluation and revision of this CPGs. That will
eventually results in better outcomes of our cardiac patients
in the region.
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